Anoro Ellipta Inhalation Powder 62.5-25Mcg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

ANORO ELLIPTA: Inhalation powder (62.5-25mcg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
ANORO ELLIPTA 62.5mcg-25mcg

What is this Medicine?

UMECLIDINIUM; VILANTEROL (ue MEK li DIN ee um; vye LAN ter ol) inhalation is a combination of two medicines that decrease inflammation and help to open up the airways of your lungs. It is for chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema. Do NOT use for asthma or an acute asthma attack. Do NOT use for a COPD attack.

CVS Pharmacy Patient Statistics for ANORO ELLIPTA: Inhalation powder(62.5-25mcg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

ANORO ELLIPTA 62.5mcg-25mcg/actuation Powder for Inhalation

NDC: 001730869
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)

Storage Information
Store in original package until time of use
Store in a dry place
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Avoid direct heat and sunlight
ANORO ELLIPTA 62.5mcg-25mcg/actuation Powder for Inhalation

Reported Side Effects for ANORO ELLIPTA 62.5mcg-25mcg/actuation Powder for Inhalation

Stomach Pain Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Heart Attack Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Vomiting Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Conjunctivitis Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Heartburn Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Irregular Heart Beat Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Cough Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Abnormal Heart Rhythm Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Itching Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Dry Mouth Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Chest Pain Incidence:
1.0%*
Severity: MODERATE
Onset: EARLY
Muscle Cramps Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Constipation Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Sore Throat Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
2.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for ANORO ELLIPTA 62.5mcg-25mcg/actuation Powder for Inhalation

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Moderate Lifestyle Interaction
Caffeine-containing Foods/Beverages and ANORO ELLIPTA 62.5mcg-25mcg/actuation Powder for Inhalation(Vilanterol)
Caffeine-containing Foods/Beverages and Beta-agonists(Vilanterol)
Limit excessive Caffeine intake (examples: coffee, teas, colas, chocolate and some herbal supplements) and limit medicines containing additional Caffeine. In caffeine-sensitive persons, taking a high amount of Caffeine with this drug can increase the risk of nausea, nervousness, palpitations, problems with sleep, rapid heartbeat, or other side effects.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with ANORO ELLIPTA

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.